June 2026 | ENDO Lab & Medical Systems
Clinical Lab Newsletter
Innovation, regulation, and strategic trends in molecular testing and remnant sample research.
June is a deadline month for laboratories. Reimbursement reporting, FDA submission changes, and accelerating investment in AI and genomics are all moving at once. The opportunity is real, but so is the operational pressure.
1
The CLFS Reporting Clock Is Running
CMS confirms that the current private-payor data reporting period runs from May 1 through July 31, 2026. Applicable laboratories must report data from the updated January 1 through June 30, 2025 collection period.
There is no phase-in reduction for 2026. Beginning in 2027, however, payment for an individual test may be reduced by as much as 15 percent per year through 2029.
Why this matters: This is no longer a future planning issue. Labs should validate applicable-laboratory status, confirm data completeness, reconcile private-payor rates and volumes, and leave time for submission corrections. Waiting until late July creates unnecessary reimbursement risk.
2
FDA Updates eSTAR and Raises the Human-Factors Bar
On June 1, FDA updated both its IVD and non-IVD eSTAR templates to incorporate the agency's new guidance on human-factors information in medical-device marketing submissions. The guidance becomes effective August 1, 2026.
FDA also expanded voluntary PreSTAR use to additional Q-Submission types, including informational meetings, study-risk determinations, submission-issue requests, PMA Day 100 meetings, and accessory-classification requests.
Why this matters: Diagnostic developers should review usability risks earlier, not during final submission assembly. Labs supporting validation studies may see more detailed requirements around intended users, use environments, workflow steps, and error mitigation.
3
Digital Pathology Moves From Pilot to Infrastructure
Roche has agreed to acquire PathAI for $750 million upfront, with up to $300 million in additional milestone payments. The transaction is expected to close in the second half of 2026, subject to customary conditions.
The deal combines Roche's diagnostics footprint with PathAI's AI-powered pathology technology and companion diagnostic capabilities. It is a strong signal that digital pathology is becoming part of the core diagnostic platform, not a side experiment.
Why this matters: Independent laboratories should evaluate scanner readiness, image quality standards, data storage, interoperability, algorithm governance, and pathologist oversight. AI may improve throughput, but weak workflow design can simply automate confusion faster.
4
Genomics Investment Accelerates the Next Sequencing Cycle
Samsung Electronics is investing $175 million in Element Biosciences, becoming the company's largest shareholder. Element plans to use the funding to expand commercialization of AVITI and VITARI and support upcoming products, including AVITI Dx and AVITI24.
Samsung has indicated that it plans to combine Element's sequencing and multi-omics capabilities with its own AI, medical-device, and digital-health expertise.
Why this matters: Competition in sequencing is widening beyond instrument performance. The next battleground will include workflow economics, clinical-grade systems, multi-omic integration, data analysis, and global scale. Labs considering new platforms should assess the complete operating model, not only cost per read.
5
Remnant Specimens: Valuable, but Compliance Must Lead
Leftover clinical specimens can accelerate IVD development, biomarker discovery, and validation while creating a new revenue stream for participating laboratories. Their value rises sharply when specimens are paired with usable clinical context and consistent pre-analytical documentation.
The compliance line matters. FDA has stated that IRB review is required for FDA-regulated clinical investigations using leftover, de-identified human specimens, even where informed-consent enforcement discretion may apply under specific circumstances.
Why this matters: A successful remnant program requires more than a freezer and a buyer. It needs defined inclusion criteria, de-identification controls, unique-patient tracking, chain of custody, storage standards, data governance, and clear study documentation.
Industry Events to Watch
ADLM 2026 Annual Meeting & Clinical Lab Expo
July 26-30 | Anaheim, California
One of the industry's largest gatherings, with the Clinical Lab Expo running July 28-30.
Next Generation Dx Summit
August 24-26 | Washington, DC
Focused on diagnostic development, liquid biopsy, biomarkers, reimbursement, and commercialization.
AMP 2026 Annual Meeting & Expo
November 10-14 | Seattle, Washington
A major molecular pathology meeting covering clinical genomics, oncology, infectious disease, and informatics.
ASCP & CAP-ACP 2026 Annual Meeting
November 17-20 | Montreal, Quebec
Education and collaboration across pathology and the full laboratory team.
If you are attending any of these events, let's coordinate time to connect. Contact David Curley at [email protected].
Attending ADLM in July?
ADLM, formerly AACC, takes place July 26-30 in Anaheim, CA. ENDO will host a nearby networking happy hour, with details to be released next month.
Our networking events are usually a big hit, giving lab professionals a simple way to meet peers from around the country, share ideas, and learn what may be working for others. We make networking easy while enjoying cocktails and food.
Good food, good cocktails, good people, and good ideas can lead to business improvement opportunities.
Please contact us if you plan to attend and we will reserve a spot for you.
Email: [email protected] or [email protected]
Could Your Lab Be Monetizing Its Remnant Specimens?
ENDO helps laboratories evaluate feasibility and build low-burden, compliant remnant collection programs that support research while creating incremental revenue.
Contact David Curley: [email protected]
ENDO Current Research Priorities
- De-identified K2/K3 EDTA whole-blood remnants with structured clinical data
- Normal and disease-state cerebrospinal fluid specimens
- FFPE tissue, including gastrointestinal, liver, prostate, pancreatic, and cardiac tissue
- Respiratory, STI, autoimmune, neurological, and other high-value remnant specimens
Quick Thought
The laboratory industry's competitive advantage is shifting from test volume alone to the quality of the entire data-and-specimen ecosystem. The winners will be the labs that can produce reliable results, document the workflow, connect the right data, and move quickly without compromising compliance.
Interesting Fact of the Month
The FDA-cleared Lumipulse Alzheimer's blood test was evaluated using 499 plasma samples from cognitively impaired adults and showed that a routine blood draw can help predict amyloid pathology that previously often required PET imaging or cerebrospinal fluid testing.
Final Thought
If these trends intersect with your current initiatives, or if you are exploring opportunities in clinical research, remnant collection, molecular testing, or laboratory growth, let's connect.
Want to Know More About ENDO Lab and Medical Systems' Capabilities and Offerings?
ENDO Lab and Medical delivers innovative products and services that enable our customers to experience better patient outcomes, faster turnaround times, increased utilization of laboratory resources, and improved profitability. Our industry expertise and personalized approach to service allows our customers to make informed decisions to grow revenue and protect their bottom line.
